Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

Brown University

Retaining Patients in Office-based Buprenorphine Treatment

Brown University via Independent

Overview

Program Release: January 25, 2021 Expiration Date: January 25, 2023 Estimated time to complete: 30 Minutes There are no prerequisites for participation. Guest Speaker Tiffany Lu, MD, MS Assistant Professor of Medicine Albert Einstein College of Medicine General Internal Medicine Physician Montefiore Medical Center | Bronx, NY Program Description: We will review the importance of patient retention in office-based buprenorphine treatment and present clinical practices and policies that promote treatment retention. We will also discuss methods to intensify treatment for patients who are unstable in office-based buprenorphine treatment. Method of Participation and How to Receive CME Credit There are no fees for participating in and receiving credit for this activity. Review the activity objectives, faculty information, and CME information prior to participating in the activity. View the CME presentations Complete the CME activity evaluation at the conclusion of the activity in order to receive a credit certificate. Faculty Disclosure In accordance with the disclosure policy of the Brown University CME Office as well as standards set forth by the Accreditation Council on Continuing Medical Education (ACCME), speakers have been asked to disclose any relevant financial relationship with the manufacturers of any commercial products and/or provider of commercial services discussed in any educational presentation and with any commercial supporters or exhibitors of this activity. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation but to identified openly so that the listener may form his/her own opinion. Any potential conflicts of interest have been resolved prior to this presentation. This activity may include discussion of off-label or investigative drugs uses. Speakers are aware that it is their responsibility to disclose to the audience this information. Individual Faculty Disclosure information may be found in the conference handouts. Faculty Disclosure/Conflict of Interest The following speaker and planning committee members have disclosed that they have no relevant financial relationships: Speaker: Tiffany Lu, MD, MS Planning Committee Members: Rahul Vanjani, MD, MSc, Maria Sullivan This presentation includes discussion of unlabeled/investigational use of a commercial product. Disclaimer and Privacy Policy Privacy Policy: The Office of Continuing Medical Education (CME) and its educational partners protect the privacy of personal and other information regarding participants and educational collaborators. The CME Office maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. The CME Office will keep your personal information confidential when you participate in a CME Internet-based program. CME collects only the information necessary to provide you with the services that you request. Disclaimer: This educational program is designed to present scientific information and opinion to Health professionals, to stimulate thought, and further investigation.

Syllabus

At the conclusion of this session, attendees should be able to:

  1. Describe the importance of patient retention in buprenorphine treatment
  2. Identify clinical practices and policies that promote buprenorphine treatment retention
  3. Review options for treatment intensification when patients are unstable in buprenorphine treatment

Reviews

Start your review of Retaining Patients in Office-based Buprenorphine Treatment

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.